Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 265

1.

[Improvements in oral anticoagulant therapy for atrial fibrillation].

Briongos Figuero S, García Santos-Gallego C, Badimón JJ.

Med Clin (Barc). 2013 Dec 7;141(11):487-93. doi: 10.1016/j.medcli.2013.02.015. Epub 2013 Apr 16. Review. Spanish.

PMID:
23597953
2.

Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.

Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):480-6. doi: 10.1161/CIRCOUTCOMES.112.965988. Epub 2012 Jul 10.

3.

Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.

Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.

Int Angiol. 2012 Aug;31(4):330-9. Review.

PMID:
22801398
4.

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

Mantha S, Ansell J.

Thromb Haemost. 2012 Sep;108(3):476-84. doi: 10.1160/TH12-02-0093. Epub 2012 Jun 28. Review.

PMID:
22740145
5.

Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.

Lip GY, Larsen TB, Skjøth F, Rasmussen LH.

J Am Coll Cardiol. 2012 Aug 21;60(8):738-46. doi: 10.1016/j.jacc.2012.03.019. Epub 2012 May 9.

6.

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.

Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ.

Am J Cardiol. 2012 Aug 1;110(3):453-60. doi: 10.1016/j.amjcard.2012.03.049. Epub 2012 Apr 24. Review.

PMID:
22537354
7.

Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.

Olesen JB, Sørensen R, Hansen ML, Lamberts M, Weeke P, Mikkelsen AP, Køber L, Gislason GH, Torp-Pedersen C, Fosbøl EL.

Europace. 2015 Feb;17(2):187-93. doi: 10.1093/europace/euu225. Epub 2014 Sep 18.

8.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
9.

New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.

Aguilar MI, Kuo RS, Freeman WD.

Neurol Clin. 2013 Aug;31(3):659-75. doi: 10.1016/j.ncl.2013.03.001. Review.

PMID:
23896498
10.

Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.

Lip GY, Kongnakorn T, Phatak H, Kuznik A, Lanitis T, Liu LZ, Iloeje U, Hernandez L, Dorian P.

Clin Ther. 2014 Feb 1;36(2):192-210.e20. doi: 10.1016/j.clinthera.2013.12.011. Epub 2014 Feb 6.

11.

Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.

Harrington AR, Armstrong EP, Nolan PE Jr, Malone DC.

Stroke. 2013 Jun;44(6):1676-81. doi: 10.1161/STROKEAHA.111.000402. Epub 2013 Apr 2.

12.

A review of oral anticoagulants in patients with atrial fibrillation.

Greenspon AJ.

Postgrad Med. 2012 Nov;124(6):7-16. doi: 10.3810/pgm.2012.11.2608. Review.

PMID:
23322134
13.

New alternative anticoagulants in atrial fibrillation: the move beyond warfarin.

Bhimani AA, Hong M.

Rev Recent Clin Trials. 2013 Jun;8(2):78-85. Review.

PMID:
23859143
14.

Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.

Cheng JW, Barillari G.

J Clin Pharm Ther. 2014 Apr;39(2):118-35. doi: 10.1111/jcpt.12122. Epub 2014 Jan 3. Review.

PMID:
24383983
15.

New agents to prevent strokes in nonvalvular atrial fibrillation.

Putney D, Pratt C.

Methodist Debakey Cardiovasc J. 2012 Jul-Sep;8(3):44-6.

16.

Target-specific oral anticoagulants: practice issues for the clinician.

Plitt A, Giugliano RP.

Hosp Pract (1995). 2014 Aug;42(3):48-61. doi: 10.3810/hp.2014.08.1117. Review.

PMID:
25255406
17.

Novel oral anticoagulants in secondary prevention of stroke.

Diener HC, Easton JD, Hankey GJ, Hart RG.

Best Pract Res Clin Haematol. 2013 Jun;26(2):131-9. doi: 10.1016/j.beha.2013.07.007. Epub 2013 Jul 30. Review.

PMID:
23953901
18.

Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.

Lanitis T, Cotté FE, Gaudin AF, Kachaner I, Kongnakorn T, Durand-Zaleski I.

J Med Econ. 2014 Aug;17(8):587-98. doi: 10.3111/13696998.2014.923891. Epub 2014 May 29.

PMID:
24831811
19.

Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation.

Turagam MK, Velagapudi P, Bongu NR, Kocheril AG.

Cardiovasc Hematol Disord Drug Targets. 2014;14(1):79-86. Review.

PMID:
25088126
20.

Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.

Skjøth F, Larsen TB, Rasmussen LH, Lip GY.

Thromb Haemost. 2014 May 5;111(5):981-8. doi: 10.1160/TH14-02-0118. Epub 2014 Feb 28.

PMID:
24577485
Items per page

Supplemental Content

Write to the Help Desk